GSK

News

GSK has made its first major acquisition under new CEO Luke Miels, buying RAPT Therapeutics and its food allergy prevention drug ozureprubart.

News

GSK will file its chronic hepatitis B virus therapy bepirovirsen for approval in the first quarter, after it hit the mark in two phase 3 trials.

News

GSK has unlocked a big new market for Nucala for COPD - China - which accounts for around a quarter of the global patient population.

News

Nine more pharma groups have agreed to lower the costs of medicines in the US under the Trump administration's most favoured nation (MFN) scheme.

News

GSK scores a first approval in the UK for new severe asthma and CRSwNP therapy Exdensur, but a second in the US covers the asthma indication only.

News

GSK is poised for the first major approval of depemokimab, a long-acting drug for severe asthma that can be dosed just twice a year.